NovoCure Company

Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.
Technology: Others
Industry: Personalized Medicine
Headquarters: Haifa, Israel
Founded Date: 2000
Employees Number: 200-500
Funding Status: IPO
Total Funding: $152M
Estimated Revenue: $50M to $100M

Visit Website
media@novocure.com
twitter.com/novocure
Register and Claim Ownership